Pfizer raised profit estimates for 2025 thanks to cost cuts, despite falling COVID product revenue and patent expirations.
Sanziana Georgescu
Economy
sursa foto: shutterstock.com
Always see our news on Google
Pfizer has announced a revised profit estimate for 2025, underpinned by a cost-cutting program, amid falling COVID product revenues and patent expirations. Shares rose 3.7% after the company reported a better-than-expected quarterly profit. However, Pfizer remains cautious, maintaining annual sales forecasts of between $61 billion and $64 billion, due to pandemic uncertainties and political pressure to cut drug prices.
Sources
Pfizer își majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri și al presiunilor politice din partea lui Trump
Pfizer își ridică prognoza de profit pentru 2025, mizând pe reduceri agresive de costuri și negocieri
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Pfizer îşi majorează estimarea de profit pentru 2025, pe fondul reducerilor masive de costuri şi al presiunilor politice din partea lui Trump
Latest News
07:09
No surprise in Russia’s parliamentary elections. Exit poll – Putin’s party wins decisively
23:03
Meteorologists announce strong winds in 13 counties and a significant cooling, with rain and snowfall in the mountains until Thursday
22:57
Zelensky and Trump have agreed to meet in New York / “The meeting could change many things”
22:44
Traian Băsescu defends Siegfried Mureșan and rejects accusations that the MEP was a German spy
22:32
Claudiu Manda announces that the PSD will not vote for the Siegfried Mureșan government and criticizes the statements made by the candidate for the position of prime minister
See more news
NEWS ON THE SAME TOPICS
.webp)
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
